<DOC>
	<DOC>NCT00748904</DOC>
	<brief_summary>The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.</brief_summary>
	<brief_title>Rifaximin Versus Lactulose in Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>cirrhosis of liver of any etiology progressive renal failure stage 02 hepatic encephalopathy pregnant women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>cirrhosis of liver and progressive renal failure</keyword>
</DOC>